By Dr Mark Theo Bloch

Journal articles

Worm SW; Bower M; Reiss P; Bonnet F; Law M; Fätkenheuer G; d'Arminio Monforte A; Abrams DI; Grulich A; Fontas E; Kirk O; Furrer H; Wit SD; Phillips A; Lundgren JD; Sabin CA; Butcher D; Delforge M; Fanti I; Franquet X; Geffard S; Gras L; Helweg-Larsen J; Hillebregt M; Kamara D; Kjær J; Krum E; McManus H; Meidahl P; Mocroft A; Nielsen J; Powderl W; Rickenbach M; Rode R; Ryom L; Salbøl Brandt R; Schmidt Iversen J; Shortman N; Sjøl A; Smith C; Torres F; Tverland J; Wright S; Zaheri S; de Wolf F; Smidt J; Ristola M; Katlama C; Viard JP; Girard PM; Livrozet JM; Vanhems P; Pradier C; Dabis F; Neau D; Rockstroh J; Schmidt R; Degen O; van Lunzen J; Stellbrink HJ; Staszewski S; Bogner J; Gargalianos P; Kosmidis J; Perdios J; Xylomenos G; Filandras A; Karabatsaki E; Panos G; Sambatakou H; Banhegyi D; Mulcahy F; Burke M; Turner D; Yust I; Hassoun G; Pollack S; Maayan S; Vella S; Esposito R; Mazeu I; Mussini C; Arici C; Pristera R; Gabbuti A; Mazzotta F; Lichtner M; Vullo V; Boer K; Geerlings SE; Godfried MH; Kuijpers TW; Lange JMA; Nellen FJB; Pajkrt D; Prins JM; Scherpbier HJ; Vrouenraets SME; Wit FWMN; van Vugt M; Cooper D; Petoumenos K; Carr A; Bloch M; Han A, 2013, 'Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study', BMC Infectious Diseases, 13, pp. 471, http://dx.doi.org/10.1186/1471-2334-13-471

Booth SM; Bloch M, 2013, 'An evaluation of a new prehospital pre-alert guidance tool', Emergency Medicine Journal, 30, pp. 820 - 823, http://dx.doi.org/10.1136/emermed-2012-201545

Cohen C; Wohl D; Arribas J; Henry K; Bloch M; Towner W; Ebrahimi R; Porter D; De-oertel S; Quercia R; Fralich T, 2013, 'STAR: Rilpivirine/Emtricitabine/TenofovirDF is non-inferior to Efavirenz/Emtricitabine/TenofovirDF in naive adult Latino, black & white subpopulations', Journal of the International AIDS Society, 16, http://dx.doi.org/10.7448/ias.16.2.18683

Russo M; Bloch M; Looze FD; Morris C; Shephard A, 2013, 'Flurbiprofen microgranules for relief of sore throat: A randomised, double-blind trial', British Journal of General Practice, 63, http://dx.doi.org/10.3399/bjgp13X663118

Smith AH; Laird C; Porter K; Bloch M, 2013, 'Haemostatic dressings in prehospital care.', Emergency medicine journal : EMJ, 30, pp. 784 - 789, http://dx.doi.org/10.1136/emermed-2012-201581

Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S, 2013, 'Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study', The Lancet, 381, pp. 735 - 743, http://dx.doi.org/10.1016/S0140-6736(12)61853-4

Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M, 2013, 'Rilpivirine versus efavirenz in hiv-1-infected subjects receiving emtricitabine/tenofovir df: Pooled 96-week data from ECHO and THRIVE studies', HIV Clinical Trials, 14, pp. 81 - 91, http://dx.doi.org/10.1310/hct1403-81

Leenders FJ; Amin J; Bloch M; Pett SL; Marriott D; Carr AD, 2013, 'Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 62, pp. 525 - 533, http://dx.doi.org/10.1097/QAI.0b013e3182832578

Schlesinger N; Alten RE; Bardin T; Schumacher HR; Bloch M; Gimona A; Krammer G; Murphy V; Richard D; So AK, 2012, 'Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions', Annals of the Rheumatic Diseases, 71, pp. 1839 - 1848, http://dx.doi.org/10.1136/annrheumdis-2011-200908

, 2012, 'Track B Clinical Science', Journal of the International AIDS Society, 15, http://dx.doi.org/10.7448/ias.15.5.18439

Nelson M; Amaya G; Clumeck N; Arns da cunha C; Jayaweera D; Junod P; Li T; Tebas P; Stevens M; Buelens A; Vanveggel S; Boven K; Abusamra L; Cahn P; Laplume HE; Cassetti I; Ceriotto M; Martins MD; Krolewiecki A; Amarilis Lugo L; Bolan R; Bush L; Corales R; Crane L; De Vente J; Fischl M; Gathe J; Greenberg R; Henry K; Jayaweera D; Kumar P; Lalezari J; Leider J; Lubelchek R; Martorell C; Mounzer K; Cohen C; Olivet H; Ortiz R; Rhame F; Roberts A; Ruane P; Scribner A; Segal-Maurer S; Short W; Sloan L; Wilkin T; Wohlfeiler M; Yangco B; Bloch M; Gold J; Hoy J; Martinez P; Baker D; Finlayson R; Roth N; Rieger A; Vetter N; Zangerle R; Da Cunha CA; Grinsztejn B; Madruga JV; Pilotto JH; Sampaio D; Gonsalez CR; Lima MP; Rangel F; Timerman A; Kilby D; Rachlis A; Walmsley S; Boissonnault M; Brunetta J; De Wet J; Gill J; Kasper K; Macleod J; Gerstoft J; Mathiesen L; Pedersen C; Cotte L; Girard PM; Molina JM; Raffi F; Vittecoq D; Yazdanpanah Y; Yeni P; Boue F; Katlama C; Reynes J; Fisher M; Nelson M; Orkin C; Taylor S; Johnson M; Wilkins E; Williams IG; Winston A; Lazzarin A, 2012, 'Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials', Journal of Antimicrobial Chemotherapy, 67, pp. 2020 - 2028, http://dx.doi.org/10.1093/jac/dks130

Twiss J; McKenna SP; Bloch M; Bonney M, 2012, 'Erratum: Patient and clinician perceived benefit of early consumption of famciclovir for the treatment of herpes outbreaks. Value in Health (2011) 14:7 (A266))', Value in Health, 15, pp. 789, http://dx.doi.org/10.1016/j.jval.2012.07.001

Carey DL; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray J; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e

Haskelberg H; Hoy J; Amin J; Ebeling PR; Emery S; Carr AD, 2012, 'Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine', PLoS ONE, 7, pp. e38377, http://dx.doi.org/10.1371/journal.pone.0038377

Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M; Van Beek I; Amin J; Dolan K; Rawlinson W; Flynn J; Marks P; Acraman B; Bloch M; Li H; Madden A; George J, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

, 2012, 'Eleventh International Congress on Drug Therapy in HIV Infection', Journal of the International AIDS Society, 15, pp. 18447 - 18447, http://dx.doi.org/10.7448/ias.15.6.18447

Koelsch KK, 2012, 'No significant effect of uridine or pravastatin treatment for HIV lip atrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomised trial.', HIV Medicine, 11, pp. 493 - 501

Cohen C; Wohl D; Arribas J; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Wang H; White K; Poulin Porter D; Guyer B; Fralich T, 2012, 'STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults', Journal of the International AIDS Society, 15, pp. 1 - 1, http://dx.doi.org/10.7448/ias.15.6.18221

Twiss J; Mckenna S; Bloch M; Bonney MA, 2011, 'PIN5 Patient and Clinician Perceived Benefit of Early Consumption of Famciclovir for the Treatment of Herpes Outbreaks', Value in Health, 14, pp. A266 - A266, http://dx.doi.org/10.1016/j.jval.2011.08.193

Amin J; Martin A; Bloch M; Carr A, 2010, 'Reply to Landman and Soonawala', Clinical Infectious Diseases, 50, pp. 1200 - 1201, http://dx.doi.org/10.1086/651469

Bloch M; Farris M; Tilden D; Gowers A; Cunningham N, 2010, 'Triple-class HIV antiretroviral therapy failure in an Australian primary care setting', Sexual Health, 7, pp. 17 - 24, http://dx.doi.org/10.1071/SH09039

Bloch M; Hoy J; Cunningham N; Roth N; Andrianopoulos N; Rayner C; Carr A, 2010, 'Adherence to HIV treatment guidelines for initiation of antiretroviral therapy in Australia', Journal of the International AIDS Society, 13, http://dx.doi.org/10.1186/1758-2652-13-s4-p172

Grebely J; Petoumenos K; Hellard M; Matthews G; Suppiah V; Applegate TL; Yeung B; Marks P; Rawlinson WD; Lloyd AROLA; Booth D; Kaldor JM; George J; Dore GJ; Amin J; Cameron B; Acraman B; Dolan K; Bloch M; Van Beek I; Li H; Madden A, 2010, 'Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection', Hepatology, 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850

Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P; Fraqueiro RL; Fraqueiro G; Pauchard CK; Pauchard M; Fontaine C; Michon C; Bensalem M; Perre P; Suaud I; Molina JM; Rachline A; Goujard C; Môle M; Arvieux C; Ratajczak M; Touam MB; Touam F; Girard PM; Lagneau JL; Raffi F; Hue H; Zucman D; de Truchis P; Berthe H; Levy Y; Jung C; Piketty C; Reynes J; Vidal M; Sereni D; Bloch M, 2009, 'Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: The 2IP ANRS 127 study', Journal of Antimicrobial Chemotherapy, 64, pp. 118 - 125, http://dx.doi.org/10.1093/jac/dkp146

Meads DM; McKenna SP; Bonney MA; Bloch MT, 2009, 'Further validation and responsiveness assessment of the herpes outbreak impact questionnaire and herpes symptom checklist', Value in Health, 12, pp. 397 - 400, http://dx.doi.org/10.1111/j.1524-4733.2008.00450.x

Mitsuyasu RT; Merigan T; Carr AD; Zack J; Winters M; Workman C; Bloch MT; Lalezari J; Becker S; Thornton L; Akil B; Khanlou H; Finlayson R; Mcfarlane R; Smith DE; Garsia R; Ma DD; Law MG; Murray JM; Von Kalle C; Ely JA; Patino S; Knop A; Wong P; Todd A; Haughton M; Fuery C; Marcpherson J; Symonds G; Evans L; Pond SM; Cooper DA; Cooper D; Han A, 2009, 'Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells', Nature Medicine, 15, pp. 285 - 292, http://dx.doi.org/10.1038/nm.1932

Martin A; Bloch MT; Amin J; Baker DL; Cooper DA; Emery S; Carr AD, 2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, 49, pp. 1591 - 1601

Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I; Ajam A; Alexander R; Aung A; Barry S; Becker B; Belbin M; Bishop C; Bisshop F; Bourne C; Brett T; Brown K; Butler A; Carmody C; Chan D; Chuah J; Conway D; Daly C; Davies S; Davis C; Davis B; Dever N; Donovan B; Eisen D; Eliades C; Elisha B; Fairley C; Feiglin A; Freeman A; Furner V; Garland S; Genn W; Giannakopoulos J; Glass F; Gold J; Goswami J; Gowers A; Grech J; Hackney P; Hanson B; Hartnell K; Harvey C; Hasan M; Hawkins S; Heley S; Herbst D; Hespe C; Irlicht M; Isaacs A; Katahanas L; Kelly M; Komarowski P; Kostic G; Kozminsky M; Lagios K; Lee D; Lewis P; Liang T; Lyttle H; Mackellar-Michelmore H; Macleod H; Marsh L; Marshall L; McCloskey J; McCurdy D; McEvoy P; McFarlane R; McKeegan P; McMurchie M; McNamee K; Medland N; Menon A; Meyerowitz C; Michaels W; Mobbs M; Montague A; Nicola N; Nurcombe C; O'Connor C; Ooi C; Ostrowskyl O; O'Sullivan M; Owen L; Papp K; Patten J; Panopoulous D; Pell C; Philpot R; Quan D; Quin J; Rhodes D, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study (Sexual Health (2008) 5, 3, (219-225))', Sexual Health, 5, pp. 379, http://dx.doi.org/10.1071/SH08013_CO

Bodsworth NJ; Bloch MT; Mcnulty A; Denham I; Doong N; Trottier S; Adena MA; Bonney M; Agnew J; Australo-Canadian Fast A, 2008, '2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study', Sexual Health, 5, pp. 219 - 225

Sabin C; Monforte A; Friis-Moller N; Weber R; El-Sadr W; Reiss P; Kirk O; Mercie P; Law MG; De Wit S; Pradier C; Phillips A; Lundgren JD, 2008, 'Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction', Clinical Infectious Diseases, 46, pp. 1101 - 1110, http://dx.doi.org/10.1086/528862

Monforte A; Abrams D; Pradier C; Weber R; Reiss P; Bonnet F; Kirk O; Law MG; de Witt S; Friis-Moller N; Phillips AN; Sabin C; Lundgren JD, 2008, 'HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.', AIDS, pp. 2143 - 2153

Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H; Baker D; Bloch M; Bodsworth N; Cooper D; Workman C; Kovacs C; Tsoukas C; Afani A; Perez J; Cortes J; Thitivichianlert S; Brown S; Crumpacker C; Galpin J; Hicks C; Kumar P; Lichtenstein K; Little S; Liporace R; Morales-Ramirez J; Santana-Bagur J; Schwartz R; Steigbigel R; Tashima K, 2007, 'Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study', Journal of Acquired Immune Deficiency Syndromes, 46, pp. 125 - 133, http://dx.doi.org/10.1097/QAI.0b013e318157131c

Fox Z; Antunes F; Davey R; Gazzard B; Klimas N; Labriola A; Losso M; Neaton JD; Phillips A; Ruxrungtham K; Staszewski S; Weiss L; Lundgren DJ; Aguilar L; Angel EB; Aquilia S; Belloso W; Benetucci J; Bittar V; Cahn P; Casiro A; Contarelli J; Corral J; Daciuk L; David D; Ferrari I; Fridman D; Galache V; Guaragna G; Ivalo S; Laplume H; Lanusse I; Lasala MB; Lattes R; Lasovsky J; Lopardo G; Lourtau L; Lupo S; Maranzana A; Marson C; Massera L; Sanchez MDL; Somenzini C; Tocci M; Algar S; Anderson J; Baker D; Blavius K; Bloch M; Boyle M; Bradford D; Britton P; Carrall L; Carr A; Chuah J; Curry M; D'Arcy-Evans C; Dobson P; Doong N; Egan C; Ferguson W; Finlayson R; French M; Frater A; Gold J; Habel P; Haig K; Holland R; Hyland N; Hoy J; Hudson J; James R; Leung J; Lowe K; MacRae K; McMurchie M; Medland N; Miller S; Murray J; Newman R; David O; Patching J; Primrose R; Ree H; Richardson R; Rogers G; Roney J; Roth N; Sarangapany J; Shaw D; Silberberg C; Skett A; Vale R; Villella C; Walker A; Watson A; Wendt N; Wood H, 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x

Lowy M; Collins S; Bloch M; Gillman M; Lording D; Sutherland P; Wang H; Stecher V, 2007, 'Quality of erection questionnaire correlates: Change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction', Journal of Sexual Medicine, 4, pp. 83 - 92, http://dx.doi.org/10.1111/j.1743-6109.2006.00398.x

Emery S; Kelleher AD; Workman C; Puls R; Bloch MT; Baker D; Hoy JF; Ip S; Nalliah K; Ward L; Law MG; Cooper DA, 2007, 'Influence of IFN gamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, 3, pp. 260 - 267

Collins S; Mertenskoetter T; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjær J; Weber R; Reisswafaamel-Sadr P; Kirk O; Dabis F; Law MG; Pradier C; De Wit S; Akerlund B; Calvo G; Monforte ADA; Ledergerber B; Phillips AN; De Wolf F; Zaheri S; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Schattenkerk JKME; Geerlings SE; Godfried MH; Lange JMA; Van Leth FC; Lowe SH; Van Der Meer JTM; Nellen FJB; Pogány K; Van Der Poll T; Reiss P; Ruys TA; Sankatsing SU; Steingrover R; Van Twillert G; Van Der Valk M; Van Vonderen MGA; Vrouenraets SME; Van Vugt MV; Wit FWMN; Van Eeden A; Ten Veen JH; Van Dam PS; Roos JC; Brinkman K; Frissen PHJ; Weigel HM; Mulder JW; Van Gorp ECM; Meenhorst PL; Mairuhu ATA; Veenstra J; Danner SA; Van Agtmael MA; Claessen FAP; Perenboom RM; Rijkeboer A; Richter C; Van Der Berg J; Van Leusen R; Vriesendorp R; Jeurissen FJF; Kauffmann RH; Koger ELW; Bravenboer B; Ten Napel CHH; Kootstra GJ; Sprenger HG; Miesen WMAJ; Doedens R; Scholvinck EH; Ten Kate RW; Van Houte DPF; Polee M; Kroon FP; Van Den Broek PJ; Van Dissel JT; Schippers EF; Schreij G; Van De Geest S, 2006, 'Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D Study', Archives of Internal Medicine, 166, pp. 1632 - 1641, http://dx.doi.org/10.1001/archinte.166.15.1632

Gold J; Batterham MJ; Rekers H; Harms MK; Geurts TBP; Helmyr PME; Silva de Mendonça J; Carvalho LHF; Panos G; Pinchera A; Aiuti F; Lee C; Horban A; Gatell J; Phanuphak P; Prasithsirikul W; Gazzard B; Bloch M; Danner SA, 2006, 'Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting', HIV Medicine, 7, pp. 146 - 155, http://dx.doi.org/10.1111/j.1468-1293.2006.00358.x

Pett SL; Wand HC; Law MG; Arduino R; Lopez JC; Knysz B; Pereira L; Pollack S; Reiss P; Tambussi G, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85

Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders J; Petoumenos K; Irvine K; Law MG; Grey PA; Finlayson R; Mcfarlane R; Kelleher AD; Carr AD; Cooper DA, 2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (Pulse)', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 42, pp. 192 - 202

Kinloch-De Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L, 2005, 'Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection', Journal of Infectious Diseases, 192, pp. 607 - 617, http://dx.doi.org/10.1086/432002

Chee CC; Mortier E; Dupont C; Bloch M; Simonpoli AM; Rouveix E, 2005, 'Medical and social differences between French and migrant patients consulting for the first time for HIV infection', AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 17, pp. 516 - 520, http://dx.doi.org/10.1080/09540120412331291760

Winston A; Bloch MT; Carr AD; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387

Ray J; Marriott D; Bloch MT; McLachlan AJ, 2005, 'Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic', British Journal of Clinical Pharmacology, 60, pp. 291 - 299

Van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJP; Schechter M; Murphy RL; Horban A; Hall DB; Lange JMA; Reiss P, 2004, 'Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1', PLoS Medicine, 1, pp. 064 - 074, http://dx.doi.org/10.1371/journal.pmed.0010019

Martin A; Smith DE; Carr AD; Hoy JF; Chuah J; Mallal SA; Law MG; Clements MS; Cooper DA, 2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, 5, pp. 192 - 200, http://thomasland.metapress.com/content/0gu76x27mmhe5ale/

Mortier E; Toure S; Seyler C; Bloch M; Anglaret X, 2003, 'Urinary pH in HIV-infected adults in Ivory Coast and in France [3]', AIDS, 17, pp. 2003 - 2005, http://dx.doi.org/10.1097/00002030-200309050-00028

Levy Y; Durier C; Krzysiek R; Rabian C; Capitant C; Lascaux AS; Michon C; Oksenhendler E; Weiss L; Gastaut JA; Goujard C; Rouzioux C; Maral J; Delfraissy JF; Emilie D; Aboulker JP; Gougeon ML; Metro A; Viard JP; Bouchenafa K; Jung C; Mortier E; Bloch M; Chandemerle C; Gérard L; Martinie M; Kazatchkine M; Laureillard D; Dinh TT; Dalmas AM; Peretti D; Rannou MT; Bazin C; Verdon R; Six M; Goubin P; Vittecoq D; Escaut L; Malet M; Maignan A; Bouvet E; Prevot MH; Fournier I; Gaudebout C; Yéni P; Belarbi L; Mandet C; Zucman D; Majerholc C; Boue F; Estocq GA; Delavalle AM; Pasquali JL; Lalanne H; Bouchet-Delbos L; Chambenoit C; Carmagnat MV; Grangeot-Keros L; Ameisen JC; Estaquier J; Monnier D; Ferchal F; Girard PM; Laplanche A; Bazin B; Foubert V; Izard S; Martins J; Netzer E, 2003, 'Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial', AIDS, 17, pp. 343 - 351, http://dx.doi.org/10.1097/00002030-200302140-00008

Kaufmann GR; Bloch MT; Finlayson RJ; Zaunders J; Smith DE; Cooper DA, 2002, 'The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy', AIDS, 16, pp. 359 - 367

Bloch M, 2001, 'Current tren HIV therapy', Current Therapeutics, 42, pp. 8 - 12

Bodsworth NJ; Bloch M; Bower M; Donnell D; Yocum R; International Panretin Gel KS Study Group , 2001, 'Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma.', Am J Clin Dermatol, 2, pp. 77 - 87, http://dx.doi.org/10.2165/00128071-200102020-00004

Back to profile page